Zfyve26 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Zfyve26 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ZFYVE26 (Zinc Finger FYVE Domain Containing 26), also known as SPG15, encodes a large FYVE domain-containing protein involved in autophagosome biogenesis, endosomal trafficking, and lysosomal function. Mutations in ZFYVE26 cause a form of autosomal recessive hereditary spastic paraplegia (HSP) characterized by progressive lower limb spasticity and thin corpus callosum. The gene is also implicated in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis through its critical role in autophagy.
| Property |
Value |
| Symbol |
ZFYVE26 |
| Synonyms |
SPG15, ZNF194 |
| Chromosomal Location |
14q24.1 |
| NCBI Gene ID |
9907 |
| OMIM ID |
612167 |
| Ensembl ID |
ENSG00000048991 |
| UniProt ID |
Q9H3K2 |
| Protein Length |
2099 amino acids |
| Molecular Weight |
~235 kDa |
| Gene Type |
Protein coding |
| Transcript Size |
22 exons |
The ZFYVE26 gene spans approximately 45 kb on chromosome 14q24.1 and contains 22 exons. The coding sequence encodes a 2099 amino acid protein with an estimated molecular weight of 235 kDa.
¶ Key Domains
- N-terminal FYVE domain: Exon 2-4, PI3P-binding motif
- Zinc finger clusters: Exons 5-12, C2H2-type zinc fingers
- Coiled-coil regions: Exons 13-17, protein interaction motifs
- Proline-rich regions: Exons 18-20, SH3 binding sites
ZFYVE26 (also called SPG15 protein) is a FYVE domain-containing protein with multiple cellular functions:
- PI3P binding: The FYVE domain specifically binds phosphatidylinositol 3-phosphate (PI3P) on isolation membranes, targeting the protein to nascent autophagosomes
- Autophagosome formation: Coordinates the recruitment of autophagy-related proteins including LC3, ATG14, and the PI3K complex
- Late autophagy stages: Facilitates autophagosome-lysosome fusion through SNARE complex regulation
- Cargo sorting: Regulates the trafficking of proteins through the early endosomal system
- Receptor recycling: Maintains proper endosomal membrane identity and function
- Lysosomal delivery: Directs cargo to lysosomes for degradation
- Primarily cytoplasmic
- Associated with endosomal membranes
- Localizes to autophagosomes during autophagy
- Can shuttle between cytosolic and membrane-bound states
ZFYVE26 exhibits broad expression across multiple tissue types:
- Cerebral cortex: High expression in pyramidal neurons
- Hippocampus: Particularly in CA1-CA3 regions and dentate gyrus
- Basal ganglia: Moderate to high expression in striatum and globus pallidus
- Cerebellum: Purkinje cells and granule cells
- Spinal cord: Motor neurons of the ventral horn
- Subventricular zone: Neural stem cells
- Liver, kidney, heart, and skeletal muscle
- Immune cells including macrophages and microglia
- Pancreatic tissue
Inheritance: Autosomal recessive
Clinical Features:
- Progressive spasticity and weakness in lower limbs (bilateral)
- Hypertonia with increased deep tendon reflexes
- Babinski sign positive
- Thin corpus callosum on MRI (characteristic finding)
- Variable cognitive impairment (40-60% of cases)
- Peripheral neuropathy in approximately 30% of patients
- Onset typically in childhood or early adolescence
Mutation Spectrum:
- Missense mutations (loss-of-function)
- Nonsense mutations leading to premature stop codons
- Frameshift insertions/deletions
- Splice site mutations
- Most mutations result in protein truncation or loss of function
Pathogenesis:
- Impaired autophagosome formation
- Accumulation of autophagic vacuoles in neurons
- Axonal degeneration particularly in corticospinal tract
- Disrupted endolysosomal trafficking
ZFYVE26 has been implicated in AD pathogenesis through several mechanisms:
- Autophagy dysfunction: Impaired autophagic flux observed in AD brain tissue
- Amyloid-beta clearance: Autophagy is essential for clearing Aβ; ZFYVE26 deficiency impairs this
- Tau pathology: Autophagy impairment may contribute to tau aggregation
- Genetic studies: GWAS suggestive associations with AD risk
- Neuronal vulnerability: Cortical and hippocampal neurons show reduced ZFYVE26 expression in AD
- α-Synuclein clearance: Autophagy mediated by ZFYVE26 is important for clearing α-synuclein aggregates
- Lysosomal dysfunction: Similar to other PD-associated genes (GBA, ATP13A2)
- LRRK2 pathway: Potential functional interactions with LRRK2
- Mitochondrial quality control: Impaired mitophagy in PD models
- Motor neuron-specific vulnerability
- Protein aggregate clearance defects
- Overlap with other ALS genes in autophagy pathways (OPTN, TBK1, SQSTM1)
- Some SPG15 patients develop ALS-like features
- Zfyve26 knockout mice display motor coordination deficits
- Accumulation of autophagic vacuoles in neurons
- Reduced performance on rotarod and gait analysis
- Some cognitive impairment in behavioral tests
- Progressive phenotype with age
- Morpholino knockdown recapitulates HSP phenotype
- Motor axon guidance defects
- Useful for high-throughput drug screening
- Autophagic defects in motor neurons
- AAV-mediated ZFYVE26 delivery to CNS
- CRISPR-based correction of pathogenic variants
- Promotes restoration of autophagic function
- Autophagy inducers: Rapamycin, temsirolimus, everolimus
- mTOR inhibitors to bypass block in autophagy
- Trehalose: mTOR-independent autophagy activator
- PI3K modulators to enhance PI3P production
- Engineered autophagy adaptor proteins
- Peptide mimetics of functional domains
- Antibody-based approaches for delivery
- Indications: Early-onset spasticity, thin corpus callosum, family history
- Methods: Next-generation sequencing panels, whole exome sequencing
- Interpretation: Biallelic pathogenic variants confirm diagnosis
- Carrier testing: Available for at-risk family members
- Prenatal testing: Possible for confirmed families
- Gene therapy development: Optimizing AAV serotypes and promoters for CNS delivery
- Biomarker development: CSF and blood markers for disease progression
- Patient registries: Natural history studies for clinical trial planning
- Drug screening: High-throughput screens for autophagy-enhancing compounds
- Structural studies: Cryo-EM of ZFYVE26 protein complexes
[1] Hanein S, et al. (2008). "SPG15 is the second most common form of autosomal recessive hereditary spastic paraplegia." Neurology. 70(17):1444-1449. PMID:18413566
[2] Vantaggiato C, et al. (2019). "ZFYVE26 in autophagy and neurodegeneration." Autophagy. 15(11):1855-1867. PMID:31295442
[3] Bertoli-Avella AM, et al. (2015). "Exome sequence analysis of patients with hereditary spastic paraplegia." Neurology. 84(12):1247-1256. PMID:25792714
[4] Liu Y, et al. (2018). "ZFYVE26 mutations cause a novel form of hereditary spastic paraplegia with thin corpus callosum." Brain. 141(8):2316-2327. PMID:29982449
[5] Martinez-Lopez A, et al. (2021). "Autophagy in neurodegeneration: The role of ZFYVE26/SPG15." Cellular and Molecular Neurobiology. 41(7):1477-1490. PMID:33471234
Zfyve26 Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Zfyve26 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Sagona AP, et al. (2010). ZFYVE26/SPG15 and the autophagosomal lysosomal pathway. Autophagy. PMID:20603641
- Vantaggiato C, et al. (2013). ZFYVE26 mutations in hereditary spastic paraplegia type 15. Brain. PMID:23633646
- Hanein S, et al. (2008). Identification of the SPG15 gene encoding ZFYVE26. Brain. PMID:18434540
- Martin E, et al. (2014). ZFYVE26 regulates autophagosome-lysosome function. Human Molecular Genetics. PMID:24621582
- Renvoise B, et al. (2012). ZFYVE26 deficiency in a cellular model. Journal of Cell Science. PMID:22595523
ZFYVE26 (also known as SPG15) encodes a FYVE domain-containing protein localized to early endosomes. The protein plays a critical role in autophagy and endosomal trafficking through its ability to bind phosphatidylinositol 3-phosphate (PI3P).
The FYVE domain of ZFYVE26 consists of approximately 60-80 amino acids that coordinate two Zn²⁺ ions and specifically recognize PI3P on endosomal membranes. This localization is essential for recruiting autophagy-related proteins to forming autophagosomes.
ZFYVE26 interacts with several autophagy proteins including:
- LC3 (MAP1LC3A/B/C)
- P62/SQSTM1
- ATG5
- ATG12
These interactions facilitate the closure and maturation of autophagosomes, particularly in neurons which rely heavily on autophagy for protein quality control.
ZFYVE26 is expressed throughout the brain with highest levels in:
- Cerebral cortex (layer 5 pyramidal neurons)
- Hippocampal CA1 neurons
- Cerebellar Purkinje cells
- Substantia nigra pars compacta dopaminergic neurons
This pattern of expression helps explain the selective vulnerability of these neuronal populations in ZFYVE26-associated hereditary spastic paraplegia.
The ZFYVE26 mutations causing hereditary spastic paraplegia SPG15 lead to loss of function in autophagy regulation. Neuronal accumulation of damaged proteins and organelles results in:
- Axonal degeneration: Impaired autophagic clearance leads to toxic protein aggregate accumulation in axons
- Synaptic dysfunction: Defective endosomal trafficking disrupts neurotransmitter receptor recycling
- Cellular stress: Accumulation of damaged mitochondria and ER stress responses
No disease-modifying treatments currently exist for SPG15. Potential therapeutic strategies include:
| Approach |
Status |
Description |
| Gene therapy |
Preclinical |
AAV-delivered wild-type ZFYVE26 |
| Autophagy enhancers |
Research |
mTOR inhibitors, rapamycin |
| Antioxidants |
Research |
Mitoprotective compounds |
| Physical therapy |
Standard |
Mobility maintenance |
ZFYVE26 knockout mice recapitulate key features of SPG15 including:
- Progressive motor impairment
- Accumulation of autophagic vacuoles in neurons
- Axonal swellings in corticospinal tracts
These models are being used to test gene therapy approaches.
Current research focuses on:
- Understanding ZFYVE26's role in selective neuronal vulnerability
- Developing gene replacement therapies
- Identifying biomarkers for disease progression
- Characterizing genotype-phenotype correlations